Oral administration of SB 204990 to rats is effectively absorbed into the systemic circulation, and its inclusion in the diet (0.05-0.25%, w/w) for one week results in a dose-related decrease in plasma cholesterol (up to 46%) and triglyceride levels (up to 80%). In dogs, SB 204990 (25 mg/kg per day) also reduces plasma cholesterol (up to 23%) and triglyceride levels (up to 38%), with a preference for lowering low-density lipoprotein cholesterol compared to high-density lipoprotein cholesterol levels^[2].

SB204990 (SB) is a specific inhibitor of the ATP-citrate lyase (ACLY) enzyme, leading to a reduction in cytosolic Ac-CoA levels and consequently expected to diminish levels of acetylated and active β-catenin^[1].